Catalent buys into new antibody tech; Mousera raises $20M;

> Catalent ($CTLT) has inked a deal with Excelimmune to get its hands on some new antibody technology, allowing the company to better manufacture combination therapies. More

> Startup Mousera raised $20 million to advance its ambitions of using Big Data to improve preclinical drug development. Story

Suggested Articles

Dr. Ian Hudson is stepping down after six years in charge of the Medicines and Healthcare products Regulatory Agency next month.

Oncology tests in the U.S. are still failing to adequately represent racial diversity, and more needs to be done to help combat this disparity.

Symphony Health has inked a new deal with Close-Up International aimed at boosting its global data services.